Although some retrospective studies have suggested the value of adjuvant therapy, no recommended standard exists in bile duct cancer. The aim of this study was to test the hypothesis that adjuvant gemcitabine chemotherapy would improve survival probability in resected bile duct cancer.
Introduction
Surgical resection offers the best chance of prolonged survival and should be considered as the first-line treatment for bile duct cancer. However, the disease often has negative prognostic features represented by larger tumour size, vascular invasion, nodal metastasis or positive resection margins 1 . Postoperative recurrence develops in over 50 per cent of patients 2, 3 , and 5-year survival remains unfavourable with a rate of 10-40 per cent 1, 4 . Adjuvant therapy has therefore been used widely after surgical resection 5, 6 , although its optimal regimen has yet to be established.
Gemcitabine has broad activity in a variety of tumours, including bile duct cancer. Early studies 7, 8 on gemcitabine in the unresectable/metastatic setting showed a response rate of 7-18 per cent, with an acceptable toxic profile in Japanese patients with unresectable biliary cancer. In 2007, the Charité Onkologie (CONKO) 001 trial 9 reported that adjuvant gemcitabine therapy had minimal toxicity and improved disease-free survival compared with observation in Western patients with resected pancreatic cancer 9 . As extrahepatic bile duct cancer partly shares embryological, clinical and pathological features with pancreatic cancer 10 , this favourable effect of gemcitabine prompted the present authors to conduct a randomized study in patients with bile duct cancer. The aim of this study was to prove the superiority of adjuvant gemcitabine over observation in patients who underwent resection for extrahepatic bile duct cancer.
Methods
The Bile Duct Cancer Adjuvant Trial (BCAT) was a randomized, open-label, multicentre phase III trial conducted at 48 Japanese hospitals. The trial was completed in accordance with the Declaration of Helsinki and the Ethical Guidelines for Clinical Studies of the Ministry of Health, Labour and Welfare of Japan. All associated medical procedures were covered by the Japanese national social insurance system. The study protocol was approved by institutional review boards in all participating centres and registered in the University Hospital Medical Information Network (http://www.umin.ac.jp; registration number ID 000000820). All patients provided written informed consent.
The primary endpoint was overall survival, and the secondary endpoints were relapse-free survival, subgroup analysis and toxicity. The trial was monitored by a data monitoring committee, which functioned independently of the investigators. Data were collected using the web-based clinical trial management system at the data centre (EPS, Osaka, Japan).
Patient eligibility
Patients with histologically proven extrahepatic bile duct cancer (perihilar and distal cholangiocarcinomas) who underwent macroscopically curative resection were enrolled in this study within 10 weeks after surgery. Other eligibility criteria for participants were pathological tumour stage I, II or III according to the UICC system, sixth edition 11 , and absence of distant metastasis or malignant ascites. Participants also had to fulfil the following criteria: possibility of adequate oral intake; aged 20 years or older; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; no history of chemotherapy or radiotherapy within the past 5 years; and adequate organ function (leucocyte count at least 3000/μl and not more than 12 000/μl; platelet count 100 000/μl or higher; haemoglobin concentration at least 8⋅0 g/dl; total bilirubin concentration 2⋅0 mg/dl or less; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) concentrations 100 units/dl or below; and serum creatinine concentration 1⋅5 mg/dl or less).
Exclusion criteria comprised: confirmed recurrence before registration; clinically significant pleural effusion or ascites; pulmonary fibrosis or interstitial pneumonia; uncontrollable diarrhoea; severe heart failure or myocardial infarction within 6 months before registration; active infectious disease; blood transfusion within 2 weeks before trial registration; severe surgical complications; other concomitant malignant disease; pregnant or lactating women; childbearing potential; or other serious disorders incompatible with the trial, based on the investigator's judgement.
Procedures
Standard surgical procedures, including pancreatoduodenectomy 3 , hepatobiliary resection 12 , hepatopancreatoduodenectomy 13 or bile duct resection, were performed with or without vascular resection 14, 15 , depending on tumour extension and institutional guidelines. Regional lymphadenectomy was carried out routinely. All required sections of a case record form were sent by fax to the coordinating data centre.
Patients were assigned randomly to either the gemcitabine or observation (surgery alone) group in a 1 : 1 ratio by a modified minimization method; participants were stratified into groups by residual tumour status (R0 versus R1), lymph node status (pN0 versus pN1), tumour location (hilar versus distal) and enrolment centre. Patients and investigators were aware of the group assignment and no placebo was used. Treatment allocation was performed centrally through a web-based randomization system managed by the data centre.
Patients assigned to the gemcitabine group received intravenous gemcitabine at a dose of 1000 mg/m 2 over 30 min on days 1, 8 and 15, followed by a rest period of 1 week (1 cycle). The dosing of gemcitabine was delayed according to the following criteria: leucocyte count below 2500/μl; platelet count less than 100 000/μl; haemoglobin concentration under 6⋅5 g/dl; total bilirubin concentration below 3⋅0 mg/dl; AST and ALT concentrations over 150 units/dl; pyrexia of 38 ∘ C or higher; uncontrolled diarrhoea; and other non-haematological adverse events which made administration of gemcitabine inappropriate. The subsequent dose of gemcitabine was reduced to 80 per cent of the initial dose and then to 60 per cent, if any of the following events occurred: leucocyte count less than 1000/μl; platelet count below 25 000/μl; serious non-haematological adverse events; or two consecutive skips of the second dose. Gemcitabine was given every 4 weeks until a total of 18 doses had been given, which was defined as completion of protocol treatment. The observation group received no anticancer treatment after surgery until disease relapse was confirmed. Protocol treatment was discontinued if any of the following occurred: recurrence; adverse events requiring further dose reduction to below 60 per cent of the intended dose; delaying the next dose for 28 days or more; patient request; difficulty in continuing the protocol treatment because of a change in the patient's personal circumstances; or other medical conditions, as judged by the investigators. During protocol treatment, laboratory tests and clinical symptoms were assessed weekly (excluding the rest week) in the gemcitabine group and monthly in the control group. Tumour markers were measured monthly; chest radiography and abdominal CT were performed every 3 months. After the period of protocol treatment, measurement of tumour markers, chest radiography and abdominal CT were repeated every 3 months during the first 3 years after enrolment, and every 6 months thereafter until the end of follow-up (at least 5 years from registration). Adverse events were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0 16 . Disease relapse was diagnosed based on radiological and/or cytological examinations. An increasing level of tumour markers alone was not considered relapse. Treatment for relapse was not prescribed by the protocol.
Statistical analysis
The results of earlier Japanese studies 17, 18 served as the basis for determining the required number of patients, and the 5-year overall survival rate in the observation group was assumed to be 30 per cent. The present authors expected a hazard ratio (HR) for mortality of 0⋅85 in the gemcitabine group compared with the observation group, and calculated that 189 events were needed to reject the null hypothesis with a statistical power of 80 per cent and two-sided α of 5 per cent. The total required sample size was 300 patients with an enrolment of 2 years, followed by an additional follow-up of 5 years. It was predefined in the protocol that survival was to be assessed in the full analysis set and in prespecified subpopulations (according to margin status, lymph node status and tumour location). Toxicity was assessed in the safety analysis population in which relevant data collection was completed.
Efficacy was evaluated in an interim analysis, which was performed by an independent data and safety monitoring committee, when 200 patients had been enrolled in the study. To control the overall α error at less than 0⋅05, multiplicity for the primary endpoint was adjusted using the O'Brien-Fleming type α spending function 19 . After interim analysis, the authors revised the protocol to extend the initial recruitment period of 2 years by 16 months owing to delayed recruitment.
Continuous data are expressed as median (i.q.r.) unless specified otherwise. Pretreatment variables between groups were compared by the Pearson χ 2 test or Mann-Whitney U test, as appropriate.
Overall survival was defined as the time from randomization to death from any cause. Relapse-free survival was defined as the time between randomization and the date of relapse or death from any cause. Data for patients who did not have an event were censored at the date of the final observation. The Kaplan-Meier method was used to estimate cumulative survival, and the log rank test for comparisons between the two test groups. HRs with 95 per cent confidence intervals were estimated by the Cox proportional hazards model. All tests were two sided and P < 0⋅050 was considered statistically significant. All statistical calculations were performed using SAS ® version 9.4 (SAS Institute, Cary, North Carolina, USA).
Results
Between 1 September 2007 and 31 January 2011, a total of 226 patients were enrolled in 48 hospitals; 117 patients were assigned randomly to the gemcitabine group and 109 to the observation group (Fig. 1) . After randomization, one patient was found to be ineligible because of stage 0 disease. The analysis included 117 patients in the gemcitabine group and 108 in the observation group.
Patient demographics and tumour characteristics were well balanced in the two groups ( Table 1 ). There were 102 perihilar and 123 distal tumours. The surgical procedures included pancreatoduodenectomy (112 patients), hepatobiliary resection (95), hepatopancreatoduodenectomy (15) and bile duct resection alone (3). Hepatectomy was performed in 110 patients (48⋅9 per cent), 108 of whom underwent major hepatectomy (right hepatectomy 51, left hepatectomy 43, left trisectionectomy 11, right trisectionectomy 3). Portal vein resection was undertaken in 35 patients (15⋅5 per cent). Pathologically, the incidence of T3/4 tumour, lymph node metastasis and positive resection margins (R1) was 55⋅1 per cent (124 patients), 34⋅7 per cent (78) and 11⋅1 per cent (25) respectively.
Toxicity and drug delivery
Grade 3/4 haematological toxicities occurred frequently in the gemcitabine group ( Table 2) ; abnormal neutrophil levels were most common (58⋅4 per cent), followed by abnormal levels of leucocytes (29⋅2 per cent), haemoglobin (7⋅1 per cent) and platelets (7⋅1 per cent). Non-haematological adverse events were rare, and comparable between the two groups.
Among 117 patients allocated to the gemcitabine group, three did not receive gemcitabine as they withdrew consent and the median relative dose intensity (RDI) was 82⋅2 (45⋅6-100) per cent. The RDI did not differ significantly between patients with versus without hepatectomy: 82⋅2 (46⋅1-100) versus 83⋅3 (39⋅2-100) per cent respectively (P = 0⋅913).
Survival analysis
At last follow-up in April 2016, median follow-up was 79⋅4 months. One patient in each group was lost to follow-up within 5 years after randomization. During the study interval, 62 patients in the gemcitabine group and 57 in the observation group died. The overall survival rate was 68⋅1 per cent at 3 years and 51⋅7 per cent at 5 years, with a median survival time (MST) of 62⋅3 months, in the gemcitabine group; it was 65⋅7 per cent at 3 years and 51⋅6 per cent at 5 years, with an MST of 63⋅8 months, in the observation group (Fig. 2a) . The HR for death in the gemcitabine group, compared with the observation group, was 1⋅01 (95 per cent c.i. 0⋅70 to 1⋅45; P = 0⋅964). The relapse-free survival rate was 50⋅9 per cent at 3 years and 45⋅7 per cent at 5 years, with an MST of 36⋅0 months, in the gemcitabine group; it was 52⋅6 per cent at 3 years and 44⋅0 per cent at 5 years, with an MST of 39⋅9 months, in the observation group (Fig. 2b) . The HR for relapse in patients receiving gemcitabine, compared with observation, was 0⋅93 (0⋅66 to 1⋅32; P = 0⋅693). Subgroup analyses, stratified according to lymph node status (pN0 versus pN1), resection margin status (R0 versus R1), tumour location (hilar versus distal) and other factors did not demonstrate significant differences in postoperative survival between the two groups (Figs 3 and 4 ; Table  S1 , supporting information). However, there were trends towards a benefit for women, and lack of benefit among patients with ECOG performance status 1.
Recurrence pattern
After 5 years of follow-up, recurrence was observed in 63 patients (53⋅8 per cent) in the gemcitabine group and 61 (56⋅5 per cent) in the observation group (P = 0⋅691) ( Table  S2 , supporting information). The location of first relapse was not significantly different between the two groups; liver was the most common site, followed by a local site, peritoneum and abdominal lymph nodes. Of the 124 patients with disease relapse, 102 (82⋅3 per cent) received treatment as follows: chemotherapy in 92, radiotherapy in nine, and surgical resection in eight patients, with some overlap.
Discussion
Because of the rarity of bile duct cancer and the extensive surgical resection for this disease, the number of surgical resections for the disease per centre has been limited 1, 4 , making it difficult to implement a randomized trial of adjuvant chemotherapy. There has been only one phase III study 20 , which was carried out over 25 years ago. This study had the following problems: outdated regimen using mitomycin C and 5-fluorouracil; inclusion of pancreatic and biliary cancers; and survival benefit found only in patients with gallbladder cancer, which could complicate its interpretation. The present randomized trial evaluated the routine use of adjuvant chemotherapy in bile duct cancer with follow-up over 5 years. This study, which was conducted in 48 centres in a single country, failed to demonstrate a significant difference in overall survival or relapse-free survival between the gemcitabine and observation groups. These findings clearly indicate that gemcitabine, which is used widely in the metastatic setting for extrahepatic bile duct cancer, probably does not work in the adjuvant setting. Thus, simple observation should be the standard approach to postoperative care in bile duct cancer, and adjuvant chemotherapy should be undertaken only in the setting of a clinical trial.
For adjuvant use of gemcitabine in pancreatic cancer, the completion rate was approximately 60 per cent and the relative dose intensity around 80 per cent 9, 21 . The most frequent grade 3/4 adverse event was an abnormal neutrophil level, with an incidence of approximately 70 per cent 21, 22 . Interestingly, the present study showed similar results regarding dose intensity and toxicity, even though the profile of the surgical procedures differed between the studies, as half of the patients here underwent major hepatectomy. Although the optimal dose modification of gemcitabine in patients who have undergone hepatectomy has rarely been addressed 23 , the present findings suggest that patients who underwent extended hepatectomy were able to tolerate gemcitabine therapy alone and support the previous observation that the pharmacokinetics of gemcitabine in patients were comparable after major hepatectomy versus pancreatoduodenectomy 24 . In this context, toxicity-associated low dose intensity is unlikely to affect the present survival results.
Several retrospective studies 25 -32 have evaluated the effect of adjuvant chemotherapy in resected biliary tract cancer. These reports have many flaws, including heterogeneous disease, limited numbers of patients, long study period and a variety of regimens. Importantly, the conclusions regarding survival benefits are conflicting. According to a systematic review 5 , a beneficial effect of adjuvant therapy was not evident in the overall analysis, but was observed in subgroups according to lymph node involvement and resection margin status. Recently, a retrospective propensity score matching analysis 33 of node-positive perihilar cholangiocarcinoma reported an increase in 5-year survival rate by 28 per cent in the adjuvant gemcitabine group compared with the observation group. Both the latter study 33 and the systematic review 5 recommended adjuvant chemotherapy in node-positive disease following resection. In contrast, the subset analysis limited to node-positive patients in the present study showed no difference in overall survival between the gemcitabine and observation groups. Rather, overall survival in the gemcitabine group was worse than in the observation group at 3 years. These results do not support the efficacy of adjuvant gemcitabine in node-positive patients. However, this subset analysis was a secondary result with a limited number of patients. Therefore, the efficacy of adjuvant chemotherapy in such a high-risk population cannot be completely ruled out.
In this study, the observed 5-year survival rate was approximately 50 per cent, which was higher than the expected rate of 30 per cent. This favourable long-term outcome can be explained by several factors relating to the trial design. Surgical outcomes generally improve over time owing to refinements in surgical technique, perioperative management or surgical indication 12 . In addition, the present study included only patients treated for extrahepatic cholangiocarcinoma, excluding gallbladder cancer. The study also excluded patients with distant metastatic disease, those who underwent R2 resection, patients with severe surgical complications and those who died in hospital. These selection criteria may have contributed to favourable survival in the present trial compared with that of the entire patient cohort who underwent resection. In fact, the number of deaths was lower than anticipated in the initial 5 years after surgery. In this respect, the survival rate at 5 years of approximately 50 per cent in patients with extrahepatic bile duct cancer can be used as the baseline rate in further randomized studies.
Four other randomized studies of routine adjuvant chemotherapy in biliary tract cancer are currently ongoing: BILCAP (capecitabine, since 2006) 34 , PRODIGE 12-ACCORD 18 (gemcitabine and oxaliplatin, since 2009) 35 , ASCOT (S-1, since 2013) and ACTICCA-1 (gemcitabine and cisplatin, since 2014) 36 . These studies will add important information on the role of adjuvant chemotherapy for resected bile duct cancer. However, the PRODIGE 12-ACCORD 18 trial 35 showed no difference in relapse-free survival between the experimental and observation groups (39 versus 33 per cent at 4 years; P = 0⋅31), similar to the present study. In contrast, the BIL-CAP trial 37 demonstrated a longer overall survival time in the capecitabine group compared with the observation group (51 versus 36 months; P = 0⋅028, in per-protocol analysis), although the intention-to-treat analysis failed to show the efficacy of adjuvant capecitabine therapy (51 versus 36 months; P = 0⋅097). The BILCAP study included R1 resection, pN1 disease and gallbladder cancer in a larger percentage of the cohort (35, 54 and 18 per cent respectively) than in the present study (11⋅1, 34⋅7 and 0 per cent). The short follow-up of at least 2 years should be considered in the BILCAP study. Overall, the results of these studies, including BCAT, suggest that combination chemotherapy does not always provide a survival benefit, and the inclusion of patients with expected favourable survival reduces the number of deaths, which potentially leads to negative results. Therefore, further clinical trials of adjuvant chemotherapy should not target all patients, but should instead focus on patients with high-risk features following resection.
A limitation of this study was that patient recruitment was terminated before the number of patients reached 300, which may have led to an underpowered analysis. Patient enrolment was considerably delayed after about 2009, mainly because most patients wanted to receive adjuvant chemotherapy. However, the survival curves for the gemcitabine and observation groups nearly overlapped. With these data in mind, there was only a 2⋅8 per cent probability of there being a statistically significant difference in overall survival even if the expected 189 deaths had occurred. Therefore, it is highly unlikely that increasing the number of patients to 300 would have affected the main results.
